Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term solid tumors. Found 17 abstracts

Chen XM, Cvetkovic D, Ma CM, Chen LL. Quantitative study of focused ultrasound enhanced doxorubicin delivery to prostate tumor in vivo with MRI guidance. Medical Physics. 2012 May;39(5):2780-6.
Patson B, Cohen RB, Olszanski AJ. Pharmacokinetic evaluation of axitinib. Expert Opinion on Drug Metabolism & Toxicology. 2012 Feb;8(2):259-70.   PMCID: not NIH funded
Wang D, Zhang Q, Blanke CD, Demetri GD, Heinrich MC, Watson JC, Hoffman JP, Okuno S, Kane JM, von Mehren M, Eisenberg BL. Phase II Trial of Neoadjuvant/adjuvant Imatinib Mesylate for Advanced Primary and Metastatic/recurrent Operable Gastrointestinal Stromal Tumors: Long-term Follow-up Results of Radiation Therapy Oncology Group 0132. Annals of Surgical Oncology. 2012 Apr;19(4):1074-80.
Giuliano M, Giordano A, Jackson S, Hess KR, De Giorgi U, Mego M, Handy BC, Ueno NT, Alvarez RH, De Laurentiis M, De Placido S, Valero V, Hortobagyi GN, Reuben JM, Cristofanilli M. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Research. 2011 Jun;13(3):R67.   PMCID: PMC3218956
Sparano JA, Goldstein LJ, Childs BH, Shak S, Brassard D, Badve S, Baehner FL, Bugarini R, Rowley S, Perez EA, Shulman LN, Martino S, Davidson NE, Kenny PA, Sledge GW, Gray R. Relationship between Quantitative GRB7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer. Clinical Cancer Research. 2011 Nov;17(22):7194-203.   PMCID: PMC3570203
Landry J, Catalano PJ, Staley C, Harris W, Hoffman J, Talamonti M, Xu N, Cooper H, Benson AB. Randomized Phase II Study of Gemcitabine Plus Radiotherapy Versus Gemcitabine, 5-Fluorouracil, and Cisplatin Followed by Radiotherapy and 5-Fluorouracil for Patients With Locally Advanced, Potentially Resectable Pancreatic Adenocarcinoma. Journal of surgical oncology. 2010 Jun;101(7):587-92.   PMCID: NIHMS351520
Welch SA, Hirte HW, Elit L, Schilder RJ, Wang L, MacAlpine K, Wright JJ, Oza AM. Sorafenib in Combination With Gemcitabine in Recurrent Epithelial Ovarian Cancer A Study of the Princess Margaret Hospital Phase II Consortium. International Journal of Gynecological Cancer. 2010 Jul;20(5):787-93.   PMCID: Not required
Rini BI, Wilding G, Hudes G, Stadler WM, Kim S, Tarazi J, Rosbrook B, Trask PC, Wood L, Dutcher JP. Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology. 2009 Sep;27(27):4462-8.   PMCID: not NIH funded
Yao K, Gietema JA, Shida S, Selvakumaran M, Fonrose X, Haas NB, Testa J, O'Dwyer PJ. In vitro hypoxia-conditioned colon cancer cell lines derived from HCT116 and HT29 exhibit altered apoptosis susceptibility and a more angiogenic profile in vivo. British Journal of Cancer. 2005 Dec 12;93(12):1356-63.
Visonneau S, Cesano A, Porter DL, Luger SL, Schuchter L, Kamoun M, Torosian MH, Duffy K, Sickles C, Stadtmauer EA, Santoli D. Phase I trial of TALL-104 cells in patients with refractory metastatic breast cancer. Clinical Cancer Research. 2000 May;6(5):1744-54.
Bookman MA, Malmstrom H, Bolis G, Gordon A, Lissoni A, Krebs JB, Fields SZ. Topotecan for the treatment of advanced epithelial ovarian cancer: An open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. Journal of Clinical Oncology. 1998 Oct;16(10):3345-52.
Iyer RV, Engelhardt EL, Stobbe CC, Schneider RF, Chapman JD. Preclinical assessment of hypoxic marker specificity and sensitivity. International Journal of Radiation Oncology Biology Physics. 1998 Nov;42(4):741-5.
Iyer RV, Kim E, Schneider RF, Chapman JD. A dual hypoxic marker technique for measuring oxygenation change within individual tumors. British Journal of Cancer. 1998 Jul;78(2):163-9.
Treat J, Johnson E, Langer C, Belani C, Haynes B, Greenberg R, Rodriquez R, Drobins P, Miller W, Meehan L, McKeon A, Devin J, von Roemeling R, Viallet J. Tirapazamine with cisplatin in patients with advanced non- small-cell lung cancer: A phase II study. Journal of Clinical Oncology. 1998 Nov;16(11):3524-7.
Hudes GR, Kosierowski R, Greenberg R, Ramsey HE, Fox SC, Ozols RF, McAleer CA, Giantonio BJ. Phase II study of topotecan in metastatic hormone-refractory prostate cancer. Investigational New Drugs. 1995 Jan;13(3):235-40.
Devries EG, Hamilton TC, Lind M, Dauplat J, Neijt JP, Ozols RF. Drug-Resistance, Supportive Care and Dose Intensity. Annals of Oncology. 1993 Jan;4:57-62.
Mannan RH, Mercer JR, Wiebe LI, Somayaji VV, Chapman JD. Radioiodinated 1-(2-Fluoro-4-Iodo-2,4-Dideoxy-Beta-L- Xylopyranosyl)-2-Nitroimidazole - a Novel Probe for the Noninvasive Assessment of Tumor Hypoxia. Radiation Research. 1992 Dec;132(3):368-74.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term solid tumors

solid tumors trial inhibitor carcinoma hypoxia growth progression therapy angiogenesis survival agent resection invitro breast-cancer renal-cell carcinoma cisplatin endothelial growth-factor antitumor-activity cells bone-marrow transplantation topoisomerase-i platinum photodynamic therapy cancer invivo murine tumors bevacizumab preoperative chemoradiation pancreaticoduodenectomy mutations receptor gemcitabine gene-expression placebo dna untwisting enzyme colony-stimulating factor platinum cyclophosphamide chemotherapy phase-ii contrast-enhanced mri pancreatic cancer diastolic blood-pressure hypoxic marker marker cyto-toxicity sr-4233 factor receptor nicotinamide human ovarian-cancer apoptosis microenvironment Gemcitabine multidrug-resistance tumor hypoxia colorectal-cancer brain colon cancer kinase peptide refractory ovarian- VEGF fractions line tall-104 s-transferase activity metabolism CA125 ovarian cancer topotecan basal-like subtype activated killer-cells carboplatin recombinant drug interleukin-2 model p-glycoprotein metastatic polymerase chain-reaction adriamycin oxygenation predicts tumor-cell high-dose gastrointestinal stromal tumors interleukin-2 receptors phase-i angiogenesis inhibitor uterine cervix radiation-therapy camptothecin 1000 bchy a-clin canc res-v16-p5351 sunitinib intraoperative tissue resistance chemotherapy reduction pain immunodeficient scid mice p53 modulation vascular endothelial growth factor full-dose gemcitabine hypoxic fraction mouse-tumors AG-013736 concurrent radiation paclitaxel supportive care disruption technetium chelate mechanism drug resistance Sorafenib radiotherapy gist diagnosis 2010 orgoulias v-j clin oncol-v28-ps15 azomycin nucleoside prostate peripheral-blood kit carbogen Antiangiogenic Ovarian cancer 1993 en ll-ultrasound in medicine and biology-v19-p67 hypoxic-specific factor long management head focused ultrasound doxorubicin-HIFU-prostate cancer double-blind soluble misonidazole binding drug-delivery liposomes VEGFR axitinib advanced cancer dose imatinib bioreducible marker radioresistance assay infusion primary peritoneal interferon-alpha in-vivo twice-weekly gemcitabine topoisomerase I multikinase guidelines
Last updated on Saturday, August 08, 2020